These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17318454)

  • 21. Risk-reduction surgery decisions in high-risk women seen for genetic counseling.
    Ray JA; Loescher LJ; Brewer M
    J Genet Couns; 2005 Dec; 14(6):473-84. PubMed ID: 16388328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The NCCN Criterion "Young Age at Onset" Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population.
    Ebrahimi E; Sellars E; Shirkoohi R; Harirchi I; Ghiasvand R; Mohebbi E; Zendehdel K; Akbari MR
    Cancer Prev Res (Phila); 2019 Nov; 12(11):763-770. PubMed ID: 31451522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.
    Obstet Gynecol; 2009 Apr; 113(4):957-966. PubMed ID: 19305347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
    Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
    Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Risk assessment for familial occurrence of breast cancer].
    Chang-Claude J; Becher H; Hamann U; Schroeder-Kurth T
    Zentralbl Gynakol; 1995; 117(8):423-34. PubMed ID: 7571905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
    Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
    Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.
    Armstrong K; Weber B; Stopfer J; Calzone K; Putt M; Coyne J; Schwartz JS
    Am J Med Genet A; 2003 Mar; 117A(2):154-60. PubMed ID: 12567413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary breast and ovarian cancer syndrome : the impact of race on uptake of genetic counseling and testing.
    Simon MS; Petrucelli N
    Methods Mol Biol; 2009; 471():487-500. PubMed ID: 19109796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tumor risk consultation for predisposed women from high risk cancer families].
    Beckmann MW; Niederacher D; Bodden-Heidrich R; Goecke TO; Kuschel B; Achnoula M; Aba F; Schnürch HG; Bender HG
    Praxis (Bern 1994); 1998 Apr; 87(15):511-5. PubMed ID: 9608246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
    Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer.
    Sutton AL; Hurtado-de-Mendoza A; Quillin J; Rubinsak L; Temkin SM; Gal T; Sheppard VB
    J Womens Health (Larchmt); 2020 Aug; 29(8):1131-1135. PubMed ID: 31794334
    [No Abstract]   [Full Text] [Related]  

  • 36. Breast cancer genetics. Implications of clinical practice.
    Olufunmilayo I; Olopade MD; Fackenthal JD
    Hematol Oncol Clin North Am; 2000 Jun; 14(3):705-25. PubMed ID: 11203330
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
    Casasanta N; Kipnis ST; Linville L; Lipinski S; Knoedler A; Marino A; McHenry A; Biagi T; Stark E; Amdur R; Denduluri N; Rodriguez P; Isaacs C; Kaltman R
    Clin Breast Cancer; 2020 Apr; 20(2):125-130. PubMed ID: 31526714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
    Prucka SK; McIlvried DE; Korf BR
    Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
    Steffen LE; Du R; Gammon A; Mandelblatt JS; Kohlmann WK; Lee JH; Buys SS; Stroup AM; Campo RA; Flores KG; Vicuña B; Schwartz MD; Kinney AY
    Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1772-1780. PubMed ID: 28971986
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.